Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 复星医药 |
|---|---|
| Other Market Stock Code | 600196 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Fosun Pharma |
|---|---|
| Stock Code | 02196 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 本公司為中國領先的醫藥健康公司,業務戰略性覆蓋醫藥健康產業價值鏈多個重要環節,核心業務為藥品研發、生產、銷售及營銷,業務分部包括製藥、藥品分銷及零售、醫療服務以及診斷產品與醫療器械。 |
| Listing Date | 2012-10-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海 普陀區 曹楊路510號9樓 郵編:200063 |
| Business Address (Hong Kong) | 香港 皇后大道東1號 太古廣場三座 28 樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | fosunpharma.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | Yes (A股) |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 11.80 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2012-10-17 to 2012-10-22 |
| Global Offering Shares | 336,070,000 shares |
| HK Public Offer Shares (Initial) | 33,607,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 302,463,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 2,240,462,364 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 14.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 3,965,626,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 9.19B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利约人民币1,166.2百万元 |
| Period-End Cash Balance | 人民币2,894.6百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2009 | 2010 | 2011 | 2012-06 |
|---|---|---|---|---|
| Profit before tax | 3,267,477 | 1,201,951 | 1,727,238 | 987,229 |
| Profit for the year | 2,567,081 | 1,000,344 | 1,385,419 | 857,769 |
Balance Sheet
| Item | 2009 | 2010 | 2011 | 2012-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 1,296,761 | 3,343,555 | 2,894,573 | 1,743,582 |
| Trade and bills receivables | 680,333 | 1,058,407 | 1,147,700 | 1,237,591 |
| Inventories | 597,993 | 932,774 | 1,123,943 | 1,230,602 |
| Total current assets | 2,831,633 | 5,879,987 | 6,049,106 | 5,284,467 |
| Total assets | 11,470,259 | 16,776,054 | 22,233,931 | 22,265,269 |
| Total current liabilities | 2,498,342 | 3,697,693 | 4,991,726 | 3,994,706 |
| Total liabilities | 4,575,116 | 7,421,056 | 10,919,990 | 10,573,769 |
| Total equity | 6,895,143 | 9,354,998 | 11,313,941 | 11,691,500 |
| Equity attributable to owners | 6,419,635 | 8,366,136 | 9,714,976 | 10,083,827 |
| Interest-bearing borrowings | 2,869,263 | 4,590,449 | 6,093,868 | 6,143,842 |
Cash Flow Statement
| Item | 2009 | 2010 | 2011 | 2012-06 |
|---|---|---|---|---|
| Net cash from operating activities | 261,869 | 203,363 | 316,650 | 230,908 |
| Net cash from investing activities | -371,043 | -262,394 | -1,706,175 | -736,884 |
| Net cash from financing activities | 374,218 | 1,820,548 | 852,632 | -462,470 |
| Net increase in cash | 265,044 | 1,761,517 | -536,893 | -968,446 |
| Depreciation of PP&E | 126,503 | 144,129 | 172,299 | 110,471 |
| Amortisation of intangible assets | 5,702 | 4,286 | 28,016 | 25,791 |
| Purchase of PP&E | -348,068 | -339,167 | -796,833 | -619,843 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 10.84 |
|---|---|
| First Day Open | HK$ 11.08 |
| First Day Change | -8.14% |
| First Day Volume | 54273500.0 |
| First Day Turnover | 588861000.0 |
| Use of Proceeds | 1、約48%或1,806.9百萬港元將用于制藥、醫藥分銷及零售、醫藥健康、診斷產品及醫療器械領域的收購及合并;
2、約19%或715.2百萬港元將用于為現有的研發項目、擴充我們的研發團隊及收購新的研發項目融資;
3、約23%或865.8百萬港元將用于償還本集團的部分帶息負債的本金及利息;
4、約10%或376.4百萬港元將用于補充本集團的營運資金。 |
Underwriting Syndicate
Joint Sponsors (4)
Overall Coordinators (4)
Joint Bookrunners (4)
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | The Prudential Insurance Company of America | 387,624,100 HKD | — | 9.77% | — | 6 months | 2013-04-30 |
| 2 | 国际金融公司 | 191,160,000 HKD | — | 4.82% | — | 6 months | 2013-04-30 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 陳玉卿,關曉暉 | — |
| Company Secretary | 喬志城、盧綺霞 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 復星高科技、復星國際、復星控股及復星國際控股各持有917,922,361股A股,佔48.20%;郭廣昌先生持有918,036,436股A股,佔48.21%;梁信軍先生持有201,968,016股A股,佔10.61%。 |
|---|




